BN Business News
Add your company to Business Communicator →

Business · 25/10/20261 min read

Positive overall survival results from the Phase III HARMONi-GI1 trial of Ivonescimab Plus Chemotherapy versus Durvalumab Plus Chemtherapy in first-line biliary tract cancer Presented at the ESMO 2026 Presidential Symposium

Summary

HONG KONG, Oct. 25, 2026 — Akeso, Inc. (HKEX: 9926. HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registration phase III HARMONi-GI1 trial (...

Original source language: PR Newswire — Global News ReleasesOpen original release →

Explore insights

Business insights →